Study Group: Byetta Prescribers for Diabetes (US)(?)
Council Members in this Study Group: 190
Request a survey with this Study Group
Leading Experts in this Study Group
![]() |
What is a GLG Leader? |
Harold Bays, MD, FACPPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Director, Diabetes Outpatient Department
SUNY Downstate Medical Center - CC
RoseMarie Pasmantier, MD, is Director of the Diabetes Outpatient Department at State University of New York at Stony Brook. Dr. Pasmantier has experience in the treatment of all metabolic disorders. Her research interests include new treatments for type II diabetes and dyslipidemia. Dr. Pasmantier has...
Division Head of Endocrinology and Metabolism
Evanston Northwestern Healthcare
Joseph Bass, MD, PhD, is Assistant Professor of Medicine and Neurobiology at Northwestern University in Illinois and Division Head of Endocrinology and Metabolism at Evanston Northwestern Healthcare. He is also the Director of a federally-funded basic research program on obesity, diabetes, and lipid...
Ronald Innerfield, MDChief, Clinical Trials & Epidemiology
The Dorothy Bullock Memorial National Diabetes Center
Ronald Innerfield, MD, FACE, is Chief of Clinical Trials and Epidemiology, Emeritus, at the National Diabetes Center. He is also Vice President of Clinical Affairs of Evidence Based Medicine, a site management organization (SMO) in Princeton. Dr. Innerfield was a primary medical reviewer at the Division...
Michael DempseyMedical Director
Johns Hopkins Diabetes Center at Suburban Hospital
Michael Dempsey, MD, is a Private Practitioner in Rockville, Maryland. He is the Medical Director of the Johns Hopkins Diabetes Center at Suburban Hospital, where he is also the Medical Director of Diabetes Education and Endocrine Subsection Chair. He is the Vice-President of the Mid-Atlantic chapter...
Clinical Professor of Medicine
University of California, Los Angeles
Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is the Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja...
Dean Traiger, MDOwner
Physicians’ Primary Care of Southwest Florida,P.L.
Dean Traiger, MD, is the Owner of Physician's Primary Care of Southwest Florida. Dr. Traiger is board certified in Family Practice and specializes in general primary care across the continuum of pediatrics, adolescent, and adult and geriatric care. He is also focused on diabetes care, hypertension,...
Assistant Professor of Medicine and Pediatrics
Rush University Medical Center
Richard Levy, MD, is an Assistant Professor of Medicine and Pediatrics at Rush University Medical Center, and is a privately practicing adult and pediatric endocrinologist and diabetologist in Illinois. Dr. Levy has conducted research on diabetes and lipid abnormalities and is currently participating...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Experts(?)
More than 50% of patients have the 3 ccomponents to qualify for diagnosis of Metabolic Syndrome.Twwo of the components,Diabetes and Obesity are present in 20-25% of them and are difficult to control.Exenatide seems to provide that benefit.
As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome.
I am a heavy user of ARB's and Tekturna. This article does not really show anything of significance. Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
Study will be ridiculed. 1) Comparator drug is not appropriate. 2) Not an outcomes study. 3) Time frame too short to be clinically significant. 4) Drug too expensive for first line use. 5) Long term safety not established.
Most Common Company Types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Physician - Director
- President
- Partner
- Physician - Division Head
- Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms


